Introduction {#s1}
============

Cardiovascular disease (CVD) is the leading cause of mortality worldwide. CVD is multifactorial, and its risk factors include stroke, hypertension, arrhythmias, and thrombosis (Mozaffarian et al., [@B17]). Platelet aggregation-induced thrombosis obstructs blood circulation, playing a central role in acute, and chronic arterial vascular diseases (Radomski et al., [@B21]). Antiplatelet drugs decrease thrombus formation, and their estimated market is worth 24 billion United States dollars (USD).

G protein-coupled P2Y receptors belong to the nucleotide receptor G protein-coupled receptor (GPCR) family and have eight mammalian subtypes (P2Y~1,\ 2,\ 4,\ 6,\ 11-14~) (Kim et al., [@B12]). P2Y~1~ and P2Y~12~ belong to the human purinergic GPCRs and can be activated by adenosine 5′-diphosphate (ADP) to induce platelet activation (Gurbel et al., [@B7]). ADP is the first small-molecular weight platelet agonist, and its receptors, such as P2Y~1~ receptors, can couple to activated phospholipase C. The activation of serotonin receptor supplements signaling through the P2Y~1~ receptor, demonstrating that it is a specific antagonist able to block ADP-induced platelet aggregation (Jin and Kunapuli, [@B9]). The human P2Y~1~ receptor protein structure and its two ligand-binding sites for the nucleotide-like antagonist MRS2500 and allosteric antagonist 1-(2-(2-tert-butylphenoxy)pyridin-3-yl)-3-(4-(trifluoromethoxy)phenyl)urea (BPTU) were reported in 2015 (Protein Database \[PDB\] ID: 4XNW, 4XNV) (Zhang et al., [@B28]). (1′R,2′S,4′S,5′S)-4-(2-Iodo-6-methylaminopurin-9-yl)-1-\[(phosphato) methyl\]-2(phosphato)bicycle\[3.1.0\]-hexane (MRS2500) is a reported antagonist candidate that exerts its effect via its unique chemical structure. This compound binds the recombinant human P2Y~1~ receptor and inhibits the platelet aggregation caused by ADP with an 50% inhibitory concentration (IC50) value in the nanomolar range. It also effectively reduces arterial thrombosis and prolongs bleeding time and has been evaluated as a prototypical antithrombotic agent both *ex vivo* and *in vivo* (Hechler et al., [@B8]). Unlike P2Y~12~R, P2Y~1~R has a highly conserved in class A GPCR residue P229. The pocket for MRS2500 binding to P2Y~1~R mainly defined by residues from the N terminus, ECL2, and its helices structures. In P2Y~1~R, the antagonist MRS2500 potentially prevents the movements of these helices and stabilized the receptor in an inactive state by interacting with helices In the P2Y~1~R--MRS2500 structure, each terminal oxygen of the two phosphates forms at least one contact with the receptor. The hydrogen bonds from 3′-phosphate with Arg195 and Thr201, meanwhile, it is engaged in two salt-bridge interactions with Lys46 at the N terminus. The 5′-phosphate forms a salt-bridge with Thr205 and makes hydrogen bonds with Asp204 and Arg310. P2Y~1~R and P2Y~12~R structures reveal very different features in binding their nucleotide-like ligands even though recognized by the same endogenous ligand ADP. Most significantly, the binding site of MRS2500 in P2Y~1~R locates much closer to the extracellular surface than the other known GPCR structures affiliated small-molecule ligand-binding sites. Due to its more safety advantage over the P2Y~1~R inhibitors of reducing bleeding liabilities than P2Y~12~R, it has been suggested to discovery as a whole new drug targets (Gachet, [@B6]). Moreover, the P2Y1R is also enrolled in other procedure in human body, such as activation of extracellular signal-regulated kinase in astrocytes and vascular inflammation (Zerr et al., [@B27]). In recent years, many study were performed on P2Y~12~R, however, the P2Y~1~R protein and its ligand pocket crystal structure was firstly reported in 2015. And P2Y~1~R has the specificity bind-model and its diversity of regulation mechanisms compared with P2Y~12~R. This give us a hit that it is easier for other unknown small-molecule can binding to the pocket and thus be a potential antagonist of P2Y~1~R.

Traditional Chinese Medicines (TCMs) is a relevant source of biological compounds with innovative mechanisms of action. Although TCMs concepts diverge from Western medicine, concepts, some correlations exist between the two systems. For example, *Huoxuehuayu* promotes blood circulation and alleviates blood stasis. Several compounds, including ligustrazine, saffionin A, resveratrol, propylgallate, notoginseng triterpenes, crudione, lerulic acid, salvianolic acid A and B, tanshinone IIA, and safflower flavin, which are extracted from the TCM herbs: *Salvia miltiorrhiza* Bge., *Rheum palmatum* L., and *Ligusticum chuanxiong* hort., can inhibit platelet aggregation induced by arachidonic acid (AA), ADP, platelet-activating factor (PAF) and collagen or thrombin both *in vivo* and *in vitro* (Chen, [@B4]). Moreover, because the mechanism of thrombosis involves multiple pathways and requires a multi-target approach for treatment, various small molecule compounds that are not limited to the TCMs activity for the treatment of platelet aggregation can be used to target different proteins, tissues and organs. Therefore, other TCM plants and their active ingredients may act on the P2Y~1~ receptor protein to inhibit platelet aggregation via an innovative approach.

Computational approaches have been widely applied to molecular biology and medicinal research. Structure-based methods, such as ligand-protein docking, are efficient and reliable tools for novel drug discovery and design. *In silico* docking can elucidate the interactions and binding mechanisms between the protein target and its suitable ligands. The Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) comprises all 499 Chinese herbs registered in the Chinese Pharmacopoeia and 29,384 ingredients (Ru et al., [@B22]). The TCMSP provides a total of twelve absorption, distribution, metabolism, and excretion (ADME)-related properties, including oral bioavailability and half-life.

The objective of this study was to use an *in silico* docking approach to investigate the potential of compounds in the TCMSP and their distributed herbs as P2Y~1~R antagonists and potential new antiplatelet drugs. In this study, we collected all the information of herbs and their contained ingredients from the TCMSP. Then performing the docking procedure of these total 29,384 compounds into the pocket structure of receptor P2Y~1~R. Analyzed results of these high efficient docked compounds, summarized there general characters such as scaffold and there distributed herbs will provide a new direction in antiplatelet drugs innovation.

Materials and methods {#s2}
=====================

Software
--------

The 2-dimensional (2D) and 3D structures of TCM compounds were drawn using ChemBioOffice 2010 (PerkinElmer Inc., Cambridge, MA, USA) and MarvinSketch V15.8 (ChemAxon Ltd., Budapest, Hungary). The P2Y~1~ protein and MRS2500 structure (PDB ID: 4XNW) were downloaded from the PDB database (<http://www.rcsb.org/pdb>) and optimized with Molecular Operating Environment (MOE) 2014.09 (Chemical Computing Group Inc., Montreal, QC, Canada). Candidate compounds were downloaded from the TCMSP database (<http://lsp.nwsuaf.edu.cn/tcmsp.php>). The chemical structure format was transformed by OpenBabelGUI (O\'Boyle et al., [@B19]) version 2.3.2 (OpenBableGUI 2006 by Chris Morley). Virtual screening was performed using Discovery Studio Client V4.5 (DS 4.5; Accelrys Inc., San Diego, CA, USA). The network and functional analyses were generated using QIAGEN\'s Ingenuity Pathway Analysis (IPA®, QIAGEN Redwood City, CA, USA; <http://www.qiagen.com/ingenuity>).

Lipinski\'s rule of five and ADME/toxicity (T) predictions
----------------------------------------------------------

Those compounds collected in the TCMSP database were evaluated for Lipinski\'s rule of five (RO5; Lipinski et al., [@B16]) before screening. Poor pharmacokinetics and toxicity are important causes of costly failures during the downstream process of drug development. This evaluation procedure was performed in DS 4.5, the "filter by Lipinski and Veber Rules" which located in "Small Molecules" module. All setting as default values which individual property thresholds according to the original publications. Their ADME/T properties (van de Waterbeemd and Gifford, [@B25]) must be predicted and are now computable with *in silico* approaches, accelerating the drug discovery process. Therefore, we can also filter and design drug-like molecules. The DS 4.5 ADME/T Description module was used to predict the pharmacokinetic properties of all candidate compounds. This program offers reliable predictions for pharmaceutically relevant properties, including aqueous solubility, blood-brain barrier penetration (BBP), cytochrome P450 2D6 inhibition, hepatotoxicity, human intestinal absorption (HIA), and plasma protein binding. The ADME/T Description predicts the physically significant descriptors of pharmaceutically relevant properties of organic molecules. The BBP-95&99 and Absorption-95&99 confidence intervals are demonstrated as four elliptical rings in the ADME/T_AlogP98 & ADME/T_PSA_2D (Y--X axis) coordinate system.

Docking analysis
----------------

The virtual screening docking process was performed with the LigandFit module. LigandFit gives the best poses at the binding site using a stochastic conformational search and the energy of the ligand-protein complex (Sato et al., [@B23]). Compounds from the TCMSP database were docked to the P2Y~1~ protein active site fit for MRS2500 reported by Zhang (Zhang et al., [@B28]). All procedures were completed using Chemistry at HARvard Molecular Mechanics (CHARMm; Brooks et al., [@B3]). The 3D multi-conformational compound molecular structures were generated using Monte Carlo algorithm-based conformational analysis and rigid body minimization completed using the Smart Minimizer module. The DockScore was adopted as the LigandFit scoring to rank the TCMSP compounds that docked into the P2Y~1~R ligand-binding pocket for MRS2500. The LigandFit docking procedure consists of the following two steps: (1) identify and select the region of the protein as the active site for docking by cavity detection and (2) dock the candidate ligands to the selected site. The docking cavity was defined using the DS site search module. For all potential drugs, the docking site was derived from the position of the MRS2500 and P2Y~1~ co-crystallized construction (PDB ID: 4XNW), and the grid resolution was set to 0.5 Å (default). The ligand-accessible grid was defined as the minimum distance between a grid point and the protein and was 2.0 Å for hydrogen and 2.5 Å for heavy atoms. This confirmed binding site was used to calculate the non-bonded interactions between all potential compounds and the P2Y~1~ receptor protein residues. The docking procedure was initiated with the generation of random ligand conformations. The following procedures were performed after a new conformation was generated: The shapes of the potential ligands were compared with the active site, and if the result was acceptable, the dock energy (DockScore) was computed between the protein and ligand trial conformation. Variable numbers of Monte Carlo steps were used to generate different ligand conformations. Scoring was performed with six scoring functions: DockScore, LigScore 1 and 2, Piecewise Linear Potential (PLP) 1 and 2, and Potential of Mean Force (PMF). We assumed that the bioactive orientations ranked by DockScore and other scoring functions were used to retain each molecule and compute the enrichment factors.

Results and discussion {#s3}
======================

Screening and structure analysis
--------------------------------

Figure [1](#F1){ref-type="fig"} summarizes the technology roadmap and the screening results after each step. In 1997, Lipinski led to the well-known "Rule of Five" (RO5) for selecting drug-like molecules, which demonstrated orally administered drugs should have good oral bioavailability in order to be effective. According to the "Rule of Five," a drug-like molecule should have no more than one of the following criterias: No more than five hydrogen bond donors, no more than 10 hydrogen bond acceptors, a molecular mass \<500 daltons, and an octanol-water partition coefficient log P not \>5. To ensure this study with a reliable and available results. All compounds need to filtered by the RO5. From the 29,384 native TCM compounds collected from the TCMSP database, 8987 compounds were filtered by Lipinski\'s rule of five and prepared for further study. Successful docking to P2Y~1~R was observed for 1656 compounds (16,317 poses), and their ADME/T descriptors were calculated (Figure [2](#F2){ref-type="fig"}, Supplementary Datasheet [1](#SM1){ref-type="supplementary-material"}). According to the DS 4.5 suggested theory, the Human Intestinal Absorption (HIA) model can embodied in ADMET plot the validate the predictions. The ADMET---Human Intestinal Absorption model predicts human intestinal absorption (HIA) after oral administration. Intestinal absorption is defined as a percentage absorbed rather than as a ratio of concentrations. A well-absorbed compound is one that is absorbed at least 90% into the bloodstream in humans. These levels are defined by the 95% (red line) and 99% (green line) confidence ellipsoids in Figure [2](#F2){ref-type="fig"}. For the ADME/T_PSA_2D, ADME/T_AlogP98 plane, two confidence ellipsoids of 95 and 99% for oral absorption surrounded most of these natural compounds. Two ellipsoids of 95 and 99% for BBP with high penetrations further refined the range of compounds suitable for clinical development as oral-intake drugs. Total view of these 1656 compounds, majority number within an acceptable range which indicated that most candidates compounds have an ideal human intestinal absorption which can further refined the range of compounds suitable for clinical development as oral-intake drugs. Candidate ligand poses can be evaluated and prioritized according to the DockScore function. Each docked compound has an optimal pose indicated by its highest DockScore. A total of 38 compounds had a DockScore above 70.0, and these presented high potential for further studies (Table [1](#T1){ref-type="table"}).

![**Methodology roadmap and major results for P2Y~1~R-related anti-thrombosis drug design from the TCMSP database**.](fphar-07-00531-g0001){#F1}

![**ADME/T prediction plots for compounds that successfully docked in P2Y~1~R (1656) from among the compounds in the TCMSP database**.](fphar-07-00531-g0002){#F2}

###### 

**Docking results of the top 38 (DockScore \> 70) and their plant sources**.

  **Molecule Name**                                                                                                                                                                   **Pubchem_CID**   **DockScore**   **TCMs**
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------- --------------- ------------------------------------------------------------------
  Ganoderic acid J                                                                                                                                                                    20055991          78.772          ***Ganoderma lucidum*** **Karst**
  Cimiside E                                                                                                                                                                          399180            78.104          ***Cimicifuga foetida*** **L**.
  6″-O-Acetylliquiritin                                                                                                                                                               101051311         77.347          ***Glycyrrhiza uralensis*** **Fisch**
  7,8-Didehydrocimigenol                                                                                                                                                              101577840         76.088          ***Cimicifuga foetida*** **L**.
  (2S,6R)-6-\[(5R,7S,10S,13R,14R,17R)-7-Hydroxy-4,4,10,13,14-pentamethyl-3,11,15-trioxo-1,2,5,6,7,12,16,17-octahydrocyclopenta\[a\]phenanthren-17-yl\]-2-methyl-4-oxoheptanoic acid   10481601          75.198          ***Ganoderma lucidum*** **Karst**
  Cimicifoetiside A                                                                                                                                                                   16019999          74.951          ***Cimicifuga foetida*** **L**.
  2′,7-Dihydroxy-4′-methoxyisoflavan-7-O-β-d-glucopyranoside                                                                                                                          /                 74.906          ***Glycyrrhiza uralensis*** **Fisch**
  Lappaol C                                                                                                                                                                           323896            74.793          *Arctium lappa* L.
  Diosgenin glucoside                                                                                                                                                                 65609             74.599          *Asparagus cochinchinensis* (Lour.) Merr.
  2-(2-Phenylethyl)-6-\[\[(5S,6R,7R,8S)-5,6,7-trihydroxy-4-keto-2-(2-phenylethyl)-5,6,7,8-tetrahydrochromen-8-yl\]oxy\]chromone                                                       14283395          74.349          *Sinapis alba* L.
  Alisol C monoacetate                                                                                                                                                                14036813          74.331          *Alisma orientale* (Samuels) Juzep.
  Ganoderic acid E                                                                                                                                                                    23247894          74.216          ***Ganoderma lucidum*** **Karst**
  Ononin                                                                                                                                                                              442813            74.078          *Hedysarum multijugum* Maxim.
  STOCK1N-49993                                                                                                                                                                       16401117          73.833          *Fritillaria cirrhosa* D. Don
  Cimigenol                                                                                                                                                                           16020000          73.833          ***Cimicifuga foetida*** **L**.
  Lappadilactone                                                                                                                                                                      11081540          73.678          *Rosa banksiae* Ait.
  Glyasperin E                                                                                                                                                                        392442            73.281          ***Glycyrrhiza uralensis*** **Fisch**
  Ganodermic acid Q                                                                                                                                                                   10436380          73.28           ***Ganoderma lucidum*** **Karst**
  Sophojaponicin                                                                                                                                                                      6326060           73.071          *Euchresta japonica* Hook. f. ex Regel *Rheum officinale* Baill.
  Picroside III                                                                                                                                                                       24121289          72.681          *Neopicrorhiza scrophulariiflora* (Pennell) D.Y.Hong
  Hirsutaside C                                                                                                                                                                       /                 72.612          *Uncaria sinensis* (Oliv.) Havil.
  Avenacoside A                                                                                                                                                                       71581001          72.551          *Lilium brownii var*. viridulum Baker
  Fichotomide I                                                                                                                                                                       11244683          72.09           *Gypsophila licentiana* Hand.-Mazz.
  Dioscoreside C_qt                                                                                                                                                                   52931427          71.807          *Dioscorea opposite* L.
  Sanggenol A                                                                                                                                                                         15233693          71.63           *Morus alba* L.
  Bisdehydroprotostemonine                                                                                                                                                            101675309         71.562          *Stemona japonica* (Blume) Miq.
  Cubebinone                                                                                                                                                                          91724200          71.561          *Litsea cubeba* (Lour.) Pers.
  9,10-Dihydrophenanthrene-9,10-diol                                                                                                                                                  99889             71.502          *Bletilla striata* (Thunb.) Rchb.f.
  Convallasaponin A                                                                                                                                                                   441883            71.339          *Polygonatum odoratum* (Mill.) Druce
  Yuccagenin                                                                                                                                                                          3083608           71.245          *Trigonella foenum-graecum* L.
  Methyl (4R)-4-\[(5R,10S,13R,14R,17R)-4,4,10,13,14-Pentamethyl-3,7,11,15-tetraoxo-2,5,6,12,16,17-hexahydro-1H-cyclopenta\[a\]phenanthren-17-yl\]pentanoate                           21633085          70.88           ***Ganoderma lucidum*** **Karst**
  Hydnocarpin                                                                                                                                                                         5489114           70.561          *Lonicera japonica* Thunb.
  Ganoderic acid C2                                                                                                                                                                   57396771          70.305          ***Ganoderma lucidum*** **Karst**
  Kaikasaponin III_qt                                                                                                                                                                 188384            70.207          *Abrus precatorius* L.
  Trifolirhizin                                                                                                                                                                       442827            70.192          *Panax notoginseng* (Burkill) F.H.Chen
                                                                                                                                                                                                                        *Pyrrosia lingua* (Thunb.) Farw.
                                                                                                                                                                                                                        *Sophora flavescens* Aiton
  Cimicifugoside H1                                                                                                                                                                   15241163          70.1            ***Cimicifuga foetida*** **L**.
  27-Hydroxywithanolide B                                                                                                                                                             44576309          70.041          *Datura metel* L.
  Kuwanon F                                                                                                                                                                           156149            70.023          *Morus alba* L.
  MRS2500                                                                                                                                                                             44448831          Control         **Synthetic Compounds**

*Bold font indicates the three ideal plants found in this article: licorice, cimicifugae, and ganoderma*.

Traditional chinese herb analysis
---------------------------------

Although many TCMs are considered useful for treating CVDs, each herb contains numerous compounds with different P2Y~1~R DockScores. A total DockScore was obtained for each herb by summing the DockScores of its compounds as recorded in the TCMSP (Figure [S1](#SM2){ref-type="supplementary-material"}). Figure [3](#F3){ref-type="fig"} shows the 10 herbs that possessed the highest total DockScores. The IPA indicated that 1890 compounds present in these 10 herbs may be considered drug candidates for hematological diseases and CVDs (Figure [S2](#SM3){ref-type="supplementary-material"}).

![**Top 10 herbs selected by estimating the number of hit compounds (orange area between bars), max DockScore (pink line) and total DockScore (blue bars)**.](fphar-07-00531-g0003){#F3}

Additional GPCRs were mapped by the software. Hydroxycarboxylic acid receptor 2 (HCAR2), a common target for the widely prescribed dyslipidemia drug niacin, is associated with platelet aggregation inhibition (Pike, [@B20]). In addition, data indicate that the proto-oncogene tyrosine-protein kinase (SRC), phosphoinositide 3-kinase (PI3K), mitogen-activated protein kinase (MAPK), N-methyl-D-aspartate receptor (NMDAR), receptor tyrosine-protein kinase erbB-2 (ERBB2), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB), and protein kinase a (Pka) pathways (Figure [4](#F4){ref-type="fig"}) are activated by the top 10 herbs.

![**IPA-mapped CVD pathway for the 1890 compounds distributed in the top 10 herbs**.](fphar-07-00531-g0004){#F4}

Candidate compound analysis
---------------------------

Sixteen compounds were associated with platelet aggregation, and all of the relevant herbs were validated in the literature, as shown in Table [2](#T2){ref-type="table"}. Among them, ascorbic acid, also known as vitamin C, is a well-known dietary antioxidant that inactivates oxygen free radicals and exerts a variety of protective effects on blood vessels and platelets (Yang et al., [@B26]). Vitexin and caffeic acid showed significant antiplatelet aggregation activity and were relatively selective inhibitors of platelet aggregation induced by AA and collagen (Afifi and Abu-Dahab, [@B1]; Lee and Bae, [@B15]). Rutin, naringin and quercetin, three flavonoid glycosides, were metabolized to phenolic acids via aglycones by human intestinal microflora and have been considered natural prodrugs with anti-platelet activity since the 1990s (Ndhlala et al., [@B18]). Esculetin is a derivative of coumarin and exists as glycosides and caffeic acid conjugates in *Cimicifugae Rhizoma* (*Cimicifuga foetida* L.) and many other medicinal plants. The systemic usage of esculetin-containing preparations has an anticoagulant effect and may interact with anticoagulant drugs, such as warfarin (Karnewar et al., [@B10]). Curcumin, a major component of turmeric, is also found in *Cimicifuga foetida* L. and inhibits arachidonate-, adrenaline-, and collagen-induced platelet aggregation. Curcumin inhibited exogenous arachidonate-produced thromboxane B~2~ (TXB~2~) in washed platelets and the incorporation of \[^14^C\]AA into platelet phospholipids. Moreover, it also inhibited the deacylation of AA-labeled phospholipids (Du et al., [@B5]). Citric acid and L-malic acid, two main organic acids in *Fructus Choerospondiatis* \[*Choerospondias axillaris* (Roxb.) Burtt et Hill\] and *Lycii Fructus* (*Lycium chinense* Mill.), possess antioxidant, anti-inflammatory, and antiplatelet aggregation activities (Tang et al., [@B24]).

###### 

**Compounds related to platelet aggregation extracted from the top 10 herbs**.

       **Compounds[^\*^](#TN1){ref-type="table-fn"}**   **CAS ID**   **Herbs**
  ---- ------------------------------------------------ ------------ -------------------------------------------
  1    3,4-Dihydroxyphenylethanol                       10597-60-1   ***Cimicifuga foetida*** **L**.
  2    Caffeic acid                                     331-39-5     ***Cimicifuga foetida*** **L**.
  3    Capsaicin                                        404-86-4     *Panax quinquefolius* L.
  4    Cetulinic acid                                   472-15-1     ***Glycyrrhiza uralensis*** **Fisch**
  5    Cholesterol                                      57-88-5      *Commiphora myrrha* (T.Nees) Engl.
  6    Chlorogenic acid                                 327-97-9     *Panax notoginseng* (Burkill) F.H.Chen
  7    Citric acid                                      43136-35-2   *Lycium chinense* Mill.
  8    Cscorbic acid                                    50-81-7      *Lycium chinense* Mill.
  9    Curcumin                                         458-37-7     ***Cimicifuga foetida*** **L**.
  10   Esculetin                                        305-01-1     ***Cimicifuga foetida*** **L**.
  11   Gallic acid                                      149-91-7     *Gynostemma pentaphyllum* (Thunb.) Makino
                                                                     ***Glycyrrhiza uralensis*** **Fisch**
                                                                     *Panax notoginseng* (Burkill) F.H.Chen
                                                                     ***Cimicifuga foetida*** **L**.
                                                                     *Curcuma zedoaria* (Christm.) Roscoe
  12   L-Malic acid                                     97-67-6      *Lycium chinense* Mill.
  13   Naringin                                         10236-47-2   ***Glycyrrhiza uralensis*** **Fisch**
  14   Quercetin                                        117-39-5     *Gynostemma pentaphyllum* (Thunb.) Makino
                                                                     *Commiphora myrrha* (T.Nees) Engl.
                                                                     *Lycium chinense* Mill.
                                                                     ***Glycyrrhiza uralensis*** **Fisch**
  15   Vitexin                                          3681-93-4    ***Glycyrrhiza uralensis*** **Fisch**
  16   Rutin                                            153-18-4     *Gynostemma pentaphyllum* (Thunb.) Makino
                                                                     *Lycium chinense* Mill.
                                                                     ***Glycyrrhiza uralensis*** **Fisch**

*Compound information provided by IPA. All compounds had clinical and/or experimental validation determined by IPA chemical database screening. Bold font indicates the three ideal plants found in this article: licorice, cimicifugae, and ganoderma*.

*Cimicifugae, Ganoderma*, and *Licorice* analysis
-------------------------------------------------

According to the dual analyses of results related to both these compounds and plants, we focused on three particular TCM herbs, *cimicifugae* (*Cimicifuga foetida* L.), *ganoderma* (*Ganoderma lucidum* Karst), and *licorice* (*Glycyrrhiza uralensis* Fisch).

*Cimicifugae* (*Cimicifuga foetida* L.) (also known as black cohosh, black snakeroot, and rattlesnake root) has a long tradition of use as a beneficial herbal remedy for joints, muscles, nerve aches, and gynecological disorders in both China and North America. *Cimicifugae* is used as an anti-inflammatory, analgesic and antipyretic remedy in TCM. However, there are few reports of its clinical use in anti-thrombosis. Sodium ferulate (SF) is an active principle compound from *cimicifugae* and has been used in TCM and approved by the State Drug Administration of China for the treatment of cardiovascular and cerebrovascular diseases. SF has antithrombotic, platelet aggregation inhibitory, and antioxidant activities in both animals and humans.

*Ganoderma* (*Ganoderma lucidum* Karst) is a popular medicinal mushroom and has been used in TCM in Asia for the past two millennia to treat numerous diseases. Its regular consumption is believed to preserve human vitality and promote longevity. *Ganoderma* has been used worldwide, and its constituents have been extensively identified; however, the biological potency of this fungus has not yet been sufficiently investigated. According to clinical observations and pharmacologic experiments, *ganoderma* can improve microcirculation in organs and increase the amount of blood. Moreover, in recent years, a series studies focused on *ganoderma* and anti-thrombosis (Kawagishi et al., [@B11]). The administration of this herb *in vitro* and *in vivo* was found to significantly inhibit ADP-induced platelet aggregation. These inhibitory effects may involve the release of intrinsic ADP from platelets or the metabolites of AA and PAF. Other research showed that purified *ganoderma* fibrinolytic protease protected mice against thrombotic death or paralysis induced by collagen and epinephrine and also activated the partial thromboplastin time (APTT) and thrombin time (TT) in rat platelets (Kumaran et al., [@B14]). The polysaccharide of *ganoderma* was also found to prolong the blood clotting and bleeding time in rats and decrease the thrombosis and fibrinogen level in blood plasma (Klupp et al., [@B13]). Evidence indicates that *ganoderma* has potential as an antithrombotic herb because of its antiplatelet activity.

*Licorice* (*Glycyrrhiza uralensis* Fisch; Chinese name Gan-cao) is one of the most indispensable crude drugs in TCM preparations (constituting \~60%), and its wide clinical use widely began in ancient Egyptian, Greek and China in the Second century B.C. *Licorice* comprises the roots of three *Glycyrrhiza* species (*Glycyrrhiza uralensis* Fisch, *Glycyrrhiza glabra* L., and *Glycyrrhiza inflata* Batalin). In traditional clinical treatment, this botanical drug is typically used for allergic-inflammatory disease, gastrointestinal problems, cancer, CVD, and bladder and kidney ailments. Approximately 300 diverse compounds have been isolated from *licorice*, including triterpene saponins and flavonoids, which are responsible for the antiviral, anti-inflammatory, antitumor, antitussive, anti-oxidant, antispasmodic, and metabolic syndrome preventive activities. However, evidence suggests that licorice has anti-thrombosis activity and can be used to treat CVDs.

These three herbs contained 14 compounds with a DockScore above 70 (Table [3](#T3){ref-type="table"}). By calculating the binding energies between P2Y~1~R and these 14 compounds, the binding efficiency and loss of conformational entropy and energy of a bound ligand can be obtained. These compounds have different ranges of ligand energies, Van der Waals energies and bond energies compared with the ligand MRS2500. However, according to CHARMm command-based calculations, all 14 have similar rotational and translational entropy values, indicating that these compounds all have the same effective binding efficiency as the original ligand MRS2500 (Figure [5](#F5){ref-type="fig"}).

###### 

**Chemical information of candidate compounds from *Cimicifuga foetida* L., *Ganoderma lucidum* Karst, *and Glycyrrhiza uralensis* Fisch**.

  **Herbs**                       **ID**   **Name**                                                                                                                                                                            **MW[^\*^](#TN2){ref-type="table-fn"}**   **AlogP**   **H-d**      **H-a**   **RB**   **NR**   **DL**   **CYP2D6 Pre**   **HPT Pre**   **PPB Pre**                         
  ------------------------------- -------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------- ----------- --------- -- --------- -------- -------- -------- ---------------- ------------- ------------- ------- ------------- -------
  *Cimicifuga foetida* L.         PD-1     methylcimicifugoside_qt                                                                                                                                                             556.81                                    3.21        1            7         6        4        0.24     −0.579352        false         0.729381      true    2.26562       true
                                  PD-2     cimiside e                                                                                                                                                                          602.89                                    3.32        4            8         5        4        0.16     −3.41278         false         −4.76741      false   −13.1301      false
                                  PD-3     cimigenol                                                                                                                                                                           488.78                                    3.53        3            5         5        4        0.40     −2.4378          false         −2.71708      true    −4.66017      false
                                  PD-4     cimicifoetiside a_qt                                                                                                                                                                532.79                                    4.30        3            7         6        4        0.33     −5.61872         false         −3.45153      true    −2.03733      true
                                  PD-5     7,8-didehydrocimigenol                                                                                                                                                              618.89                                    2.05        5            9         6        4        0.15     −3.64524         false         −3.68623      true    1.14555       true
  *Ganoderma lucidum* Karst       PD-6     ganodermic acid O                                                                                                                                                                   528.70                                    1.17        2            8         6        4        0.79     −2.62642         false         −3.11195      true    0.987057      true
                                  PD-7     ganoderic acid J                                                                                                                                                                    514.72                                    2.29        2            7         6        4        0.81     −4.73633         false         −6.3584       false   −0.353049     true
                                  PD-8     ganoderic acid E                                                                                                                                                                    512.70                                    2.25        1            7         6        4        0.81     −4.23523         false         −4.08921      true    −0.00661775   true
                                  PD-9     ganoderic acid C2                                                                                                                                                                   518.76                                    2.37        4            7         5        4        0.81     −3.1875          false         −9.81044      false   1.39596       true
                                  PD-10    (2S,6R)-6-\[(5R,7S,10S,13R,14R,17R)-7-hydroxy-4,4,10,13,14-pentamethyl-3,11,15-trioxo-1,2,5,6,7,12,16,17-octahydrocyclopenta\[a\]phenanthren-17-yl\]-2-methyl-4-oxoheptanoic acid   514.72                                    2.29        2            7         3        8        0.81     −9.70253         false         −12.8998      false   −4.17637      false
                                  PD-11    methyl (4R)-4-\[(5R,10S,13R,14R,17R)-4,4,10,13,14-pentamethyl-3,7,11,15-tetraoxo-2,5,6,12,16,17-hexahydro-1H-cyclopenta\[a\]phenanthren-17-yl\]pentanoate                           470.66                                    2.69        0            6         3        8        0.81     −9.06642         false         −9.62875      false   −2.87221      false
  *Glycyrrhiza uralensis* Fisch   PD-12    6″-O-acetylliquiritin                                                                                                                                                               444.47                                    2.33        3            9         1        7        0.82     −6.31325         false         −6.56771      false   −1.12272      true
                                  PD-13    glyasperin E                                                                                                                                                                        444.51                                    6.41        2            6         3        7        0.75     −7.23522         false         −7.38604      false   −1.11392      true
                                  PD-14    2′,7-Dihydroxy-4′-methoxyisoflavan-7-O-β-d-glucopyranoside.                                                                                                                         434.48                                    0.59        5            9         3        8        0.73     −9.10824         false         −8.00786      false   −3.38568      false

*MW, molecular weight; AlogP, log of the octanol-water partition coefficient according to Ghose and Crippen\'s method; H-d, H-donors; H-a, H-acceptors; RB, number of rotatable bonds, defined as single bonds between heavy atoms that are both not in a ring and not terminal, i.e., connected to a heavy atom that is attached to only hydrogens. As a special case, amide C-N bonds are not rotatable; NR, base rings, defined as the number of rings in the smallest set of smallest rings (SSSR); DL, drug-likeness index; CYP2D6P, cytochrome P450 2D6 prediction; HPT Pre, hepatotoxic prediction; PPB Pre, plasma protein binding capability prediction*.

![**Comparison of 14 compounds in the binding model structure with MRS2500**.](fphar-07-00531-g0005){#F5}

A drug-likeness (DL) analysis was performed to determine whether these compounds have potential uses as drugs. The DL index values of these compounds were calculated using the Tanimoto coefficient and are presented in the TCMSP database. A molecule with DL \> 0.18 was considered a drug-like compound and was selected for the following processes. Cytochrome P450 2D6 (CYP2D6) is involved in the metabolism of a wide range of substrates in the liver, and its inhibition is related to most drug-drug interactions. The CYP2D6 model can predict candidate compounds for CYP2D6 enzyme inhibition; therefore, investigating CYP2D6 inhibition is a required part of the regulatory procedures involved in the drug discovery and development process. Discovery Studio ADME/T Descriptors contain a computational model for compounds inhibiting the CYP2D6 enzyme, which was developed from a training set of 151 structurally diverse compounds with known CYP2D6 inhibition constants. This experiment was performed with modified Bayesian learning, and all 14 compounds scored below the cutoff Bayesian score of 0.161 and were not classified as CYP2D6 inhibitors. Therefore, these compounds are unlikely to have drug-drug interactions and can improve the efficiency and safety of drugs, which has significant clinical importance. The hepatotoxicity model can predict potential organ toxicity and was developed from the available literature data for 436 compounds known to exhibit liver toxicity or trigger dose-related elevated aminotransferase levels in more than 10% of the human population. For these 14 compounds, eight had no hepatotoxic activity, including four compounds from licorice (Table [4](#T4){ref-type="table"}).

###### 

**P2Y~1~R binding energies for compounds PD-1\~PD-14**.

  **Compound**   **Ligand energy**   **Improper energy**   **Angle energy**   **Dihedral energy**   **Electrostatic energy**   **Van der Waals energy**   **RMS gradient**   **Bond energy**   **Rotational entropy**   **Translational entropy**   **Ligand entropic energy[^\*^](#TN3){ref-type="table-fn"}**
  -------------- ------------------- --------------------- ------------------ --------------------- -------------------------- -------------------------- ------------------ ----------------- ------------------------ --------------------------- -------------------------------------------------------------
  MRS2500        112.642             0.01780               37.4877            18.4862               31.3132                    4.02                       27.0966            21.3167           38.0197                  32.3073                     −20.968
  PD-1           132.048             0.08685               53.3583            115.673               −34.8348                   −21.7701                   14.3482            19.5344           38.0119                  32.3052                     −20.965
  PD-2           158.233             0.00162               40.7545            118.223               −0.04683                   −23.6102                   8.53944            22.9105           38.5017                  32.5422                     −21.1817
  PD-3           173.499             0.00000               95.1922            83.3181               −11.2569                   −14.6189                   8.2638             20.864            37.2045                  31.9167                     −20.6085
  PD-4           137.537             0.00781               35.496             85.7151               −38.3119                   35.2412                    25.7248            19.3887           37.7349                  32.1738                     −20.8433
  PD-5           326.639             0.60045               50.483             136.935               27.8459                    90.152                     67.7923            20.6223           38.8614                  32.6203                     −21.3123
  PD-6           80.7362             0.13864               26.5836            75.593                −35.1109                   0.98494                    17.0155            12.547            37.7973                  32.1509                     −20.8551
  PD-7           85.0095             0.13282               30.6886            85.335                −32.4446                   −10.3341                   15.0403            11.6317           37.2454                  31.8042                     −20.5871
  PD-8           104.733             0.06613               31.4111            89.5891               −38.5655                   9.27464                    20.1861            12.9572           37.6091                  32.071                      −20.7751
  PD-9           72.005              0.10815               26.9039            75.2766               −34.1692                   −8.48898                   16.572             12.3746           37.9219                  32.0593                     −20.8649
  PD-10          123.831             0.11197               31.7549            102.652               −40.3419                   15.6907                    18.6129            13.9629           38.125                   32.0942                     −20.9359
  PD-11          77.6839             0.07226               27.2305            82.7531               −33.2483                   −11.1572                   14.5606            12.0335           37.7967                  32.071                      −20.8311
  PD-12          51.0403             0.02020               13.3322            38.6903               −31.9949                   −5.449                     27.1373            36.4415           37.2514                  31.6337                     −20.5381
  PD-13          113.581             0.00089               13.4249            43.8391               16.1906                    4.25157                    21.2566            35.8735           37.303                   31.5659                     −20.5333
  PD-14          100.668             0.03287               8.12721            44.1692               8.49017                    −6.09511                   25.1593            45.9435           37.5527                  31.634                      −20.628

*Ligand entropic energy, rotational and translational entropy of the ligand (kcal/mol); rotational entropy, rotational entropy calculated from the principal moments of inertia for the ligand (kcal/mol); translational entropy, corrected translational entropy for the ligand (kcal/mol)*.

The scaffold and pharmacophore are two basic elements of drug molecules. The pharmacophore consists of discrete atoms, groups, and fragments responsible for the physic-chemical features, and their arrangement controls the specific activities. However, the pharmacophore must incorporate an integrated scaffold to form an actual molecule, and thus, implanting the same pharmacophore on various scaffolds results in structurally diverse compounds that act on the same biological target. The promiscuity of receptors indicates that scaffolds can be rationally transformed based on the flexibility and plasticity of the receptors, thereby imbuing receptor binding sites with diversity and variability. Compared to traditional high-throughput screening methods, the scaffold-based approach can facilitate higher initial synthetic efforts guided by the co-crystal structure.

Among these 14 compounds, two triterpene scaffolds are found in 10 compounds. Scaffold 1 was found in compounds PD-4, 5, 6, 7, 8, and 9, whereas scaffold 2 was found in compounds PD-11, 12, 13, and 14 (Figure [6](#F6){ref-type="fig"}). These two scaffolds could be further developed into more potent and selective drug-like ligands by an iterative process including co-crystallography of the complex constructed by candidate compounds with the P2Y~1~R protein. These candidate compounds could subsequently be used for chemical syntheses followed by structure-guided computational design. An ideal DL scaffold should not only form key interactions with the protein target but also possess a conserved binding mode that can tolerate small substitutions.

![**Two types of scaffolds in *Cimicifuga foetida* L., *Ganoderma lucidum* Karst, and *Glycyrrhiza uralensis* Fisch**.](fphar-07-00531-g0006){#F6}

Conclusion {#s4}
==========

Platelet aggregation occurs when platelets adhere to each other at sites of vascular injury. This process has long been recognized as critical for hemostatic plug formation and thrombosis, which is the final product of the aggregated platelets that formed a platelet plug. Vitamin K antagonists and warfarin are often taken orally to reduce thromboembolic occurrence; however, both of these drugs have an unwanted side effect of an increased risk of bleeding.

Uncontrolled platelet aggregation is critical in thrombosis, which may cause heart attacks, unstable angina and other systematic disorders. The inhibition of platelet aggregation is fundamentally important in the treatment and prevention of CVDs. Platelet aggregation can regulated by G protein-coupled P2Y receptor families, particularly P2Y~12~ and P2Y~1~ (Aslam et al., [@B2]). P2Y~1~ is required for platelet shape change in response to ADP and is also a principal receptor in mediating both physiological and pathological ADP-induced platelet aggregation. At higher ADP concentrations, P2Y~1~-deficient platelets become partially aggregated. *In vivo*, the bleeding time was increased by the lack of P2Y~1~ expression, which could protect against collagen- and ADP-induced thrombosis. It is sufficient to block ADP-induced platelet aggregation by utilize specific antagonists inhibit the signaling through P2Y1 receptor (Jin and Kunapuli, [@B9]).

MRS2500 is a new antiplatelet drug that has strong antithrombotic activity in systemic thromboembolism induced by adrenaline infusion. In P2Y~1~R, the antagonist MRS2500 may prevent the movement of P2Y~1~R helix structures and stabilize the receptor in an inactive state. The nucleotide-like antagonist MRS2500 of P2Y~1~R has numerous anchor points on different receptor domains in hydrophilic and charged sites. The interactions of both P2Y~1~ and P2Y~12~R with their nucleotide ligands reveal disparate binding modes between these two P2YR subfamilies, broadening our understanding of the diversity of signal-recognition mechanisms in GPCRs and providing additional potential ligands and diversity binding models to regulate the proteins of these subfamilies. MRS2500 has is an ideal antagonist of P2Y~1~R that can prevent platelet aggregation caused by thrombosis.

The pharmacological actions of TCMs activate blood and resolve stasis to treat thrombosis. Many Traditional Chinese herbs and Chinese patent medicines are widely applied in clinical use to treat thrombosis and have good prospects in Chinese Medicine. These drugs are used for promoting blood circulation for removing blood stasis (PBCRBS) and are involved in the clinical treatment of cardiovascular-related diseases, particularly as anti-thrombosis agents. Compared to Western medicines, TCM herbs have advantages of mild action, multiple pathways, multiple targets, and fewer adverse reactions. According to the network pharmacology analysis of PBCRBS herbs, the most frequently used TCMs contain *Danshen* (*Salvia miltiorrhiza* Bge.), *Chuanxiong* (*Ligusticum chuanxiong* hort), *Honghua* (*Carthamus tinctorius* L.), *Sanqi* (*Panax notoginseng* Burk), and *Danggui* \[*Angelica sinensis* (Oliv.) Diels\]. However, analyzing these herbs and their compounds revealed that they mainly exerted anti-thrombosis activity by affecting the nitric oxide synthase 2 (NOS2), prostaglandin-endoperoxide synthase 2 (PTGS2), tumor necrosis factor (TNF), and interleukin 1 beta (IL-1β) pathways. Currently, no research into the application of these herbs/compounds to P2Y~1~ receptors is available. Because the construction of MRS2500 and the combination model between MRS2500 and P2Y~1~R has been established, numerous TCMs can be utilized to treat thrombosis in a novel and mild manner. A combination of antiplatelet dugs is more efficient than a single drug at inhibiting the multiple pathways of platelet activation. Furthermore, natural compounds extracted from herbs have fewer side effects than synthetic compounds. We investigated the herbs and their compounds with anti-platelet aggregation activities similar to those of MRS2500.

Overall, in this study, a total of 8987 compounds from TCMs filtered by Lipinski\'s rule of five were predicted have ideal oral-intake properties. Among them, 1656 compounds distributed in 443 herbs were able to dock into the P2Y~1~R-MRS2500 structure in 16,317 poses. A total of 38 compounds had a DockScore above 70.0 and may have significant potential for development into anti-thrombosis drugs. We also investigated *Cimicifuga foetida* L., *Ganoderma lucidum* Karst and *Glycyrrhiza uralensis* Fisch. These herbs and their chemical constituents have not been widely used in anti-thrombosis treatment and may have potential as new drugs for the inhibition of platelet aggregation.
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**Total original DockScores of compounds collected from TCMSP**.
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**Total plants DockScore results analysis**. (Blue columns represent total DockScore and Orange polyline represents the tendency of the highest DockScore of each plant).
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**Canonical pathway analysis calculated in Ingenuity Pathway Analysis (IPA)**.
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